EmboCept® S DSM 50 µm
Effective short-term chemoembolization microspheres are an adjuvant in the intra-arterial treatment of inoperable liver and lung tumors and used in combination with cytostatic agents.
Effective short-term chemoembolization
EmboCept® S DSM 50 µm are degradable starch microspheres (DSM) for transarterial chemoembolization (TACE) in liver and lung tumors (TPCE).
Broad application range
EmboCept® S DSM 50 µm microspheres are used as an adjuvant therapy in the intra-arterial treatment of inoperable liver and lung tumors, in combination with cytostatic agents.
Key Features
- Biodegradable: Made from hydrolyzed starch, EmboCept® S DSM 50 µm is enzymatically degraded by endogenous alpha-amylases, allowing vascular reperfusion within approximately 90 minutes.
- Short-Term Vessel Occlusion: In vitro half-life of 30–40 minutes which enables controlled, temporary occlusion, enhancing tumor necrosis while preserving organ function. Clinical data showing tumor necrosis and response in DSM-treated patients demonstrates that EmboCept S’s transient occlusion is sufficient for therapeutic effect and tumor devascularization.
- Tightly Calibrated Particles: With 95% of particles measuring between 20–90 µm, EmboCept® S DSM 50 µm provides optimal and predictable vessel occlusion and allows deeper penetration into the tumor vasculature.
- Broad Compatibility: Can be combined with a wide range of chemotherapeutic agents, making it a flexible tool in interventional oncology.
- Repeatable: Enables multiple applications at short intervals, supporting ongoing patient treatment plans.
- Versatile Application: Suitable for superselective treatments of single liver segments or targeted lobe-specific treatments of multifocal and non-visible tumors.
Know more about
EmboCept® S DSM 50 µm
- Simple application.
- Well tolerated.
- Boosts tumor necrosis due to temporary ischemia.
- Preserves function of target organ over time.
- Degradability of DSM allows vascular reperfusion after approximately 90 minutes.
- Can be combined with a broad range of chemotherapeutic drugs.
- Repeated applications possible at short time-intervals.
Explore clinical evidence and published studies on EmboCept®
Controlling Colorectal Cancer Liver Metastases with DSM-TACE
As EmboCept® S DSM 50 μm is degradable DSM-TACE can be successfully used to treat colorectal (CRC) liver metastases, permitting multiple treatments.
DSM-TACE for Ovarian Cancer Liver Metastases
The use of DSM-TACE offers an effective treatment option for liver metastases from ovarian cancer patients refractory after standard therapy.
